← FDA DRUG APPROVALS
FDA ANDA · ANDA040888
METHYLPREDNISOLONE SODIUM SUCCINATE
Sponsor: SAGENT PHARMS INC
APPLICATION
ANDA040888
TYPE
ANDA
ORIGINAL APPROVAL
2011-07-18
LATEST ACTION
2020-02-14
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
METHYLPREDNISOLONE SODIUM SUCCINATEPrescription
METHYLPREDNISOLONE SODIUM SUCCINATE EQ 1GM BASE/VIAL · INJECTABLE · INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATEPrescription
METHYLPREDNISOLONE SODIUM SUCCINATE EQ 125MG BASE/VIAL · INJECTABLE · INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATEPrescription
METHYLPREDNISOLONE SODIUM SUCCINATE EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATEPrescription
METHYLPREDNISOLONE SODIUM SUCCINATE EQ 500MG BASE/VIAL · INJECTABLE · INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATEPrescription
METHYLPREDNISOLONE SODIUM SUCCINATE EQ 40MG BASE/VIAL · INJECTABLE · INJECTION
Approval history
2020-02-14Labeling · Supplement 4 · standardAP
2020-02-14Labeling · Supplement 3 · standardAP
2020-02-14Labeling · Supplement 1 · standardAP
2011-07-18OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.